Suppr超能文献

使用脂质纳米颗粒递送干扰素-β信使核糖核酸货物进行原位肿瘤疫苗接种

In Situ Tumor Vaccination Using Lipid Nanoparticles to Deliver Interferon-β mRNA Cargo.

作者信息

Kimura Kenji, Aicher Aidan, Niemeyer Emma, Areesawangkit Phurin, Tilsed Caitlin, Fong Karen P, Papp Tyler E, Albelda Steven M, Parhiz Hamideh, Predina Jarrod D

机构信息

Division of Pulmonary Allergy and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

出版信息

Vaccines (Basel). 2025 Feb 13;13(2):178. doi: 10.3390/vaccines13020178.

Abstract

In situ cancer vaccination is a therapeutic approach that involves stimulating the immune system in order to generate a polyclonal, anti-tumor response against an array of tumor neoantigens. Traditionally, in situ vaccination approaches have utilized adenoviral vectors to deliver immune-stimulating genes directly to the tumor microenvironment. Lipid nanoparticle (LNP)-mediated delivery methods offer several advantages over adenoviral delivery approaches, including increased safety, repeated administration potential, and enhanced tumor microenvironment activation. To explore in situ vaccination using LNPs, we evaluated LNP-mediated delivery of a reporter gene, mCherry, and an immune-stimulating gene, IFNβ, in several in vitro and in vivo models of lung cancer. In vitro experiments demonstrated successful transfection of murine cancer cell lines with LNPs carrying both mCherry and IFN-β mRNA, resulting in high expression levels and IFNβ production. In vivo studies using LLC.ova flank tumors showed that intratumoral injection of IFNβ-mRNA LNPs led to significant IFNβ production within the tumor microenvironment, with minimal systemic exposure. Therapeutic efficacy was evaluated by injecting established LLC.ova flank tumors with IFNβ-mRNA LNPs bi-weekly for two weeks. Treated tumors showed significant growth inhibition compared to controls. Flow cytometric analysis of tumor-infiltrating leukocytes revealed that tumors injected with IFNβ-mRNA LNPs were associated with an increased CD8:CD4 T-cell ratio among lymphocytes, more CD69-expressing CD8 T-cells, and an increased presence of M1 macrophages. Efficacy and an abscopal effect were confirmed in a squamous cell carcinoma model, MOC1. No toxicity was observed. These findings show that intratumoral LNP delivery of immune-stimulating mRNA transcripts, such as IFNβ, can effectively stimulate local anti-tumor immune responses and warrants further investigation as a potential immunotherapeutic approach for cancer.

摘要

原位癌症疫苗接种是一种治疗方法,它通过刺激免疫系统来产生针对一系列肿瘤新抗原的多克隆抗肿瘤反应。传统上,原位疫苗接种方法利用腺病毒载体将免疫刺激基因直接递送至肿瘤微环境。脂质纳米颗粒(LNP)介导的递送方法相对于腺病毒递送方法具有多个优势,包括更高的安全性、可重复给药的潜力以及增强的肿瘤微环境激活作用。为了探索使用LNP进行原位疫苗接种,我们在几种肺癌的体外和体内模型中评估了LNP介导的报告基因mCherry和免疫刺激基因IFNβ的递送。体外实验表明,携带mCherry和IFN-β mRNA的LNP成功转染了小鼠癌细胞系,导致高表达水平和IFNβ产生。使用LLC.ova侧腹肿瘤的体内研究表明,瘤内注射IFNβ-mRNA LNP导致肿瘤微环境内产生显著的IFNβ,全身暴露最小。通过每两周向已建立的LLC.ova侧腹肿瘤注射IFNβ-mRNA LNP两周来评估治疗效果。与对照组相比,治疗后的肿瘤显示出显著的生长抑制。对肿瘤浸润白细胞的流式细胞术分析表明,注射IFNβ-mRNA LNP的肿瘤与淋巴细胞中CD8:CD4 T细胞比例增加、更多表达CD69的CD8 T细胞以及M1巨噬细胞的存在增加有关。在鳞状细胞癌模型MOC1中证实了疗效和远隔效应。未观察到毒性。这些发现表明,瘤内LNP递送免疫刺激mRNA转录本,如IFNβ,可以有效刺激局部抗肿瘤免疫反应,作为一种潜在的癌症免疫治疗方法值得进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edc0/11861666/c950be6c3a0d/vaccines-13-00178-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验